Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has issued a warning letter to Aurobindo Pharma's antibiotics manufacturing unit in Hyderabad, India.
Subscribe to our email newsletter
Based on a field alert report for packaging and labeling compliance for unit III, the FDA has asked the company for submitting a detailed action plan on rectifying the situation.
In its warning letter, the FDA has also asked Aurobindo Pharma for submitting the action plan within 15 working days.
The company has requested the FDA for the meeting date and is in the process of submitting a detailed action plan.